PYC Therapeutics Limited (AU:PYC) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PYC Therapeutics Limited reports significant advancements in the treatment of Retinitis Pigmentosa type 11 (RP11) with their investigational drug candidate showing promising improvements in visual function in patients. Two participants in a clinical trial experienced clinically meaningful enhancements in their vision four months post-treatment. The company is moving forward with higher-dose and multiple-dose trials, aiming for a ‘proof of concept’ ahead of a planned registrational study.
For further insights into AU:PYC stock, check out TipRanks’ Stock Analysis page.